• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

[Usefulness of bone gammagraphy versus tumor markers (PSA/PAP) in monitoring cancer of the prostate].

作者信息

Morote J, de Torres J A

机构信息

Servicio de Urología, Hospital Valle Hebrón, Barcelona.

出版信息

Actas Urol Esp. 1990 Jul-Aug;14(4):268-70.

PMID:1702258
Abstract

In this paper, data obtained through bone gammagraphia, prostatic specific antigen and prostatic acid phosphatase in 159 measurements carried out in 76 patients with treated prostate cancer, 41 locoregional and 35 metastatic, is compared. Sensitivity to detect progression was higher for PSA (89% in LR and 92% in M) versus bone GF (22% in LR an 83% in M) and PAP (11% in LR and 79% in M). The results indicate that it is possible to use bone gammagraphia optimizing its efficacy.

摘要

相似文献

1
[Usefulness of bone gammagraphy versus tumor markers (PSA/PAP) in monitoring cancer of the prostate].
Actas Urol Esp. 1990 Jul-Aug;14(4):268-70.
2
Serum osteocalcin measurements in prostate carcinoma patients with skeletal deposits shown by bone scintigram: comparison with serum PSA/PAP measurements.骨闪烁显像显示有骨骼转移的前列腺癌患者血清骨钙素测定：与血清前列腺特异抗原/前列腺酸性磷酸酶测定结果的比较
J Nucl Med. 1990 Sep;31(9):1486-9.
3
Contribution of bone scintigraphy, prostatic acid phosphatase and prostate-specific antigen to the monitoring of prostatic cancer.骨闪烁显像、前列腺酸性磷酸酶及前列腺特异性抗原在前列腺癌监测中的作用
Eur Urol. 1988;14(1):1-5. doi: 10.1159/000472885.
4
Clinical usefulness of prostate-specific antigen and prostatic acid phosphatase in patients with prostatic cancer.前列腺特异性抗原和前列腺酸性磷酸酶在前列腺癌患者中的临床应用价值。
Tumour Biol. 1990;11(6):289-94. doi: 10.1159/000217664.
5
Systematic association of PAP and PSA determinations to bone scintigraphy in prostatic cancer.前列腺癌中前列腺酸性磷酸酶（PAP）和前列腺特异性抗原（PSA）测定与骨闪烁显像的系统性关联。
Am J Clin Oncol. 1988;11 Suppl 2:S68-70. doi: 10.1097/00000421-198801102-00016.
6
Prostate-specific antigen as a unique routine test in monitoring therapy for inoperable prostate cancer: comparison with radionuclide bone scan and prostatic acid phosphatase.前列腺特异性抗原作为监测不可切除前列腺癌治疗的独特常规检查：与放射性核素骨扫描及前列腺酸性磷酸酶的比较
Eur Urol. 1995;27(4):295-300. doi: 10.1159/000475184.
7
Predicting radionuclide bone scan findings in patients with newly diagnosed, untreated prostate cancer: prostate specific antigen is superior to all other clinical parameters.预测新诊断、未治疗前列腺癌患者的放射性核素骨扫描结果：前列腺特异性抗原优于所有其他临床参数。
J Urol. 1991 Feb;145(2):313-8. doi: 10.1016/s0022-5347(17)38325-8.
8
The clinical utility of prostate-specific antigen and bone scintigraphy in prostate cancer follow-up.前列腺特异性抗原和骨闪烁显像在前列腺癌随访中的临床应用。
J Nucl Med. 1991 Jul;32(7):1387-90.
9
[Role of the markers PAP-PSA in the diagnosis of cancer of the prostate].
Minerva Urol Nefrol. 1990 Apr-Jun;42(2):73-5.
10
Evaluation of PSA, free PSA, PSMA, and total and bone alkaline phosphatase levels compared to bone scans in the management of patients with metastatic prostate cancer.在转移性前列腺癌患者的管理中，将前列腺特异性抗原（PSA）、游离PSA、前列腺特异性膜抗原（PSMA）以及总碱性磷酸酶和骨碱性磷酸酶水平与骨扫描进行比较的评估。
Prostate. 1997 Oct 1;33(2):141-6. doi: 10.1002/(sici)1097-0045(19971001)33:2<141::aid-pros8>3.0.co;2-n.